{"downloaded": true, "htmlmade": false, "full": {"id": "31728405", "source": "MED", "pmid": "31728405", "pmcid": "PMC6851126", "fullTextIdList": {"fullTextId": "PMC6851126"}, "doi": "10.1038/s41531-019-0095-3", "title": "Endogenous alpha-synuclein monomers, oligomers and resulting pathology: let's talk about the lipids in the room.", "authorString": "Killinger BA, Melki R, Brundin P, Kordower JH.", "authorList": {"author": [{"fullName": "Killinger BA", "firstName": "Bryan A", "lastName": "Killinger", "initials": "BA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "1Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612 USA."}}}, {"fullName": "Melki R", "firstName": "Ronald", "lastName": "Melki", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "2CEA and Laboratory of Neurodegenerative Diseases, Institut Francois Jacob (MIRCen), CNRS, 92265 Fontenay-Aux-Roses cedex, France."}}}, {"fullName": "Brundin P", "firstName": "Patrik", "lastName": "Brundin", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "3Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI 49503 USA."}}}, {"fullName": "Kordower JH", "firstName": "Jeffrey H", "lastName": "Kordower", "initials": "JH", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "1Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612 USA."}}}]}, "dataLinksTagsList": {"dataLinkstag": "altmetrics"}, "journalInfo": {"volume": "5", "journalIssueId": "2775599", "dateOfPublication": "2019", "monthOfPublication": "0", "yearOfPublication": "2019", "printPublicationDate": "2019-01-01", "journal": {"title": "NPJ Parkinson's disease", "ISOAbbreviation": "NPJ Parkinsons Dis", "medlineAbbreviation": "NPJ Parkinsons Dis", "NLMid": "101675390", "ISSN": "2373-8057", "ESSN": "2373-8057"}}, "pubYear": "2019", "pageInfo": "23", "abstractText": "Alpha-synuclein is an intrinsically disordered, highly dynamic protein that pathogenically aggregates into inclusion structures called Lewy bodies, in several neurogenerative diseases termed synucleinopathies. Despite its importance for understanding disease, the oligomerization status of alpha-synuclein in healthy cells remains unclear. Alpha-synuclein may exist predominantly as either a monomer or a variety of oligomers of different molecular weights. There is solid evidence to support both theories. Detection of apparent endogenous oligomers are intimately dependent on vesicle and lipid interactions. Here we consider the possibility that apparent endogenous alpha-synuclein oligomers are in fact conformations of membrane-bound alpha-synuclein and not a bona fide stable soluble species. This perspective posits that the formation of any alpha-synuclein oligomers within the cell is likely toxic and interconversion between monomer and oligomer is tightly controlled. This differs from the hypothesis that there is a continuum of endogenous non-toxic oligomers and they convert, through unclear mechanisms, to toxic oligomers. The distinction is important, because it clarifies the biological origin of synucleinopathy. We suggest that a monomer-only, lipid-centric view of endogenous alpha-synuclein aggregation can explain how alpha-synuclein pathology is triggered, and that the interactions between alpha-synuclein and lipids can represent a target for therapeutic intervention. This discussion is well-timed due to recent studies that show lipids are a significant component of Lewy pathology.", "affiliation": "1Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612 USA.", "publicationStatus": "epublish", "language": "eng", "pubModel": "Electronic-eCollection", "pubTypeList": {"pubType": ["review-article", "Review", "Journal Article"]}, "keywordList": {"keyword": ["Molecular biology", "Neuroscience"]}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1038/s41531-019-0095-3"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6851126"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6851126?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "7", "hasData": "N", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCreation": "2019-11-16", "firstIndexDate": "2019-11-16", "fullTextReceivedDate": "2020-07-09", "dateOfRevision": "2020-09-29", "electronicPublicationDate": "2019-11-12", "firstPublicationDate": "2019-11-12"}, "htmllinks": "https://europepmc.org/articles/PMC6851126", "abstract": "Alpha-synuclein is an intrinsically disordered, highly dynamic protein that pathogenically aggregates into inclusion structures called Lewy bodies, in several neurogenerative diseases termed synucleinopathies. Despite its importance for understanding disease, the oligomerization status of alpha-synuclein in healthy cells remains unclear. Alpha-synuclein may exist predominantly as either a monomer or a variety of oligomers of different molecular weights. There is solid evidence to support both theories. Detection of apparent endogenous oligomers are intimately dependent on vesicle and lipid interactions. Here we consider the possibility that apparent endogenous alpha-synuclein oligomers are in fact conformations of membrane-bound alpha-synuclein and not a bona fide stable soluble species. This perspective posits that the formation of any alpha-synuclein oligomers within the cell is likely toxic and interconversion between monomer and oligomer is tightly controlled. This differs from the hypothesis that there is a continuum of endogenous non-toxic oligomers and they convert, through unclear mechanisms, to toxic oligomers. The distinction is important, because it clarifies the biological origin of synucleinopathy. We suggest that a monomer-only, lipid-centric view of endogenous alpha-synuclein aggregation can explain how alpha-synuclein pathology is triggered, and that the interactions between alpha-synuclein and lipids can represent a target for therapeutic intervention. This discussion is well-timed due to recent studies that show lipids are a significant component of Lewy pathology.", "Keywords": ["Molecular biology", "Neuroscience"], "pdflinks": "https://europepmc.org/articles/PMC6851126?pdf=render", "journaltitle": "NPJ Parkinson's disease", "authorinfo": ["Killinger BA", "Melki R", "Brundin P", "Kordower JH"], "title": "Endogenous alpha-synuclein monomers, oligomers and resulting pathology: let's talk about the lipids in the room."}